Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK
Gayatri Amirthalingam
, Heather Whitaker, Tim Brooks, Kevin Brown, Katja Hoschler, Ezra Linley, Ray Borrow, Colin Brown, Nick Watkins, David J. Roberts, Danielle Solomon, Charlotte M. Gower, Olivier le Polain de Waroux, Nick J. Andrews, and Mary E. Ramsay
Author affiliations: Public Heath England, London, UK (G. Amirthalingam, H. Whitaker, K. Brown, K. Hoschler, C. Brown, D. Solomon, C.M. Gower, O. le Polain de Waroux, N.J. Andrews, M.E. Ramsay); Public Health England, Porton Down, UK (T. Brooks); Public Health England, Manchester, UK (R. Borrow); National Health Service Blood and Transplant, Cambridge, UK (N. Watkins); National Health Service Blood and Transplant, Oxford, UK (D.J. Roberts); Radcliffe Department of Medicine, University of Oxford, Oxford (D.J. Roberts)
Main Article
Figure 2
Figure 2. Results for serum samples tested for severe acute respiratory syndrome coronavirus 2 Ig with all 3 assays, by epidemiologic week of sample collection (weeks 13,15–16,and 18), London, UK, 2020. Values are no. (%) of reactive test results. RBD, receptor-binding domain.
Main Article
Page created: April 19, 2021
Page updated: June 16, 2021
Page reviewed: June 16, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.